India's Gufic BioSciences rises as COVID-19 treatments boost results

Gufic Biosciences

12/08/2021 07:08

** Drugmaker's shares  GUFI.NS  jumped as much as 7% to
205.60 rupees, their biggest intraday pct gain since July 7
    ** Gufic BioSciences reports a profit of 312.1 million
rupees ($13,469.10) for the June-quarter compared to a loss of
14.3 million rupees a year ago  urn:newsml:reuters.com:*:nFWN2PI1NW
    ** Co also report a more than four-fold jump in quarterly
revenue to 2.51 billion rupees
    ** Gufic saw growth in its contract manufacturing business
driven by the production of COVID-19 treatments, remdesivir and
liposomal amphotericin-B  
    ** GUFI is up more than 75% YTD


($1 = 74.2440 Indian rupees)

 (Reporting by Shivani Singh in Bengaluru)
 ((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))